HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO FS.COM - The Concerns Behind the Business Model and the Outlook

Pre-IPO Videotimes Technology Holdings - Expected to See Performance Decline Due to Tariff War

Pre-IPO Hangzhou Tongshifu Cultural and Creative Group - Potential for Future Growth Is Questionable

Equity Capital Markets

Wuhan Ammunition Life-Tech / Equity Capital Markets

<ul>
<li>The products of Ammunition play more of an auxiliary and supplementary role compared to the gold standards that have been widely recognized and used in the industry for many years.</li>
<li>The concern is the clinical application may be limited due to doctors' lack of sufficient trust/recognition on such products.So, Ammunition needs to invest heavily in doctor education and market promotion.</li>
<li>The market may give more conservative valuations to enterprises that are still in the stage of "burning money" to gain market share. Valuation of Ammunition could be lower than peer</li>
</ul>


The products of Ammunition play more of an auxiliary and supplementary role compared to the gold standards that have been widely recognized and used in the industry for many years.
The concern is the clinical application may be limited due to doctors' lack of sufficient trust/recognition on such products.So, Ammunition needs to invest heavily in doctor education and market promotion.
The market may give more conservative valuations to enterprises that are still in the stage of "burning money" to gain market share. Valuation of Ammunition could be lower than peer


Pre-IPO Wuhan Ammunition Life-Tech - About The Products and the Concerns Behind